Treatment indications informed by a priori implant information

• US 20090157055A1
• Filed: 12/20/2007
• Published: 06/18/2009
• Est. Priority Date: 12/18/2007
• Status: Active Grant

• Current Assignee: Gearbox LLC (Intellectual Ventures LLC)
• Original Assignee: Searete LLC A Limited Liability Corporation of The State of Delaware
• Inventors: Ishikawa, Muriel Y., Ferren, Bran, Wood, Lowell L. JR., Rivet, Dennis J., Hyde, Roderick A., Wood, Victoria Y.H., Leuthardt, Eric C.
• Granted Patent: US 8,409,132 B2
• Time in Patent Office: Days
• US Class Current: 604/891.100
• CPC Class Codes: A61B 5/145 Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissuemeasuring of blood pressure or blood flow A61B5/02; non-radiation detecting or locating of foreign bodies in blood A61B5/06
• CPC Class Codes: A61M 2005/1726 the body parameters being measured at, or proximate to, the infusion site
• CPC Class Codes: A61M 2039/2413 designed to reduce and or shut-off the flow when a certain maximum flow limit is exceeded
• CPC Class Codes: A61M 2039/242 designed to open when a predetermined pressure or flow rate has been reached, e.g. check valve actuated by fluid
• CPC Class Codes: A61M 2039/248 Ball-valve
• CPC Class Codes: A61M 2205/04 implanted
• CPC Class Codes: A61M 2205/3561 local, e.g. within room or hospital
• CPC Class Codes: A61M 2205/3592 using telemetric means, e.g. radio or optical transmission
• CPC Class Codes: A61M 31/00 Devices for introducing or retaining media, e.g. remedies, in cavities of the body A61M25/00 takes precedence ; introducing or retaining ophthalmic products into the ocular cavities A61F9/0008
• CPC Class Codes: A61M 39/24 Check- or non-return valves
• CPC Class Codes: A61M 5/14276 specially adapted for implantation
• CPC Class Codes: G16H 20/17 delivered via infusion or injection
• CPC Class Codes: G16H 70/60 relating to pathologies

Abstract

Systems and methods are described for implementing or deploying therapeutic administration systems for obtaining a priori implant information and signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants: or obtaining a flow-change-indicative measurement and signaling a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement; or obtaining one or more indications of a lactic material in a vicinity of one or more body lumens and accelerating a decrease in a local concentration of the lytic material in the vicinity of the one or more body lumens by causing one or more elements to extract at least a portion of the lytic material in the vicinity of the one or more body lumens in response to the one or more indications of the lytic material in the vicinity of the one or more body lumens; or one or more capture components configured to accelerate a decrease in a local concentration of one or more therapeutic structures along a downstream portion of a vasculature and one or more dispensation components configured to release the one or more therapeutic structures into an upstream portion of the vasculature.

Claims

1-118. -118. (canceled)

119. A therapeutic administration system comprising:

a processor;

one or more instructions operable by the processor to obtain a flow-change-indicative measurement; and

one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement.

120. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to obtain a flow-change-indicative measurement comprise:

one or more instructions operable by the processor to program an implantable device.

121. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to obtain a flow-change-indicative measurement comprise:

one or more instructions operable by the processor to obtain turbulence-indicative auditory value as the flow-change-indicative measurement.

122. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to obtain a flow-change-indicative measurement comprise:

one or more instructions operable by the processor to detect one or more conditions optically.

123. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to obtain a flow-change-indicative measurement comprise:

one or more instructions operable by the processor to detect one or more force-change-indicative values.

124. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:

one or more instructions operable by the processor to decide upon at least one of the one or more clot-reducing agents in response to obtaining an anomalous value as the flow-change-indicative measurement.

125. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:

one or more instructions operable by the processor to at least an anticoagulant of the one or more clot-reducing agents in response to an apparent flow degradation.

126. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:

one or more instructions operable by the processor to cause one or more dispensations in response to an apparent problem in the flow-change-indicative measurement.

127. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:

one or more instructions responsive to a flow-force-responsive element.

128. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:

one or more instructions responsive to an optical sensor.

129. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:

one or more instructions responsive to an auditory sensor.

130. The therapeutic administration system of claim 119, further comprising:

a wireless-communication device.

131. The therapeutic administration system of claim 119, further comprising:

a thrombolytic-agent-containing dispenser responsive to the decision whether to administer the one or more clot-reducing agents.

132. The therapeutic administration system of claim 119, further comprising:

an implantable valve comprising at least one dispenser responsive to the decision whether to administer the one or more clot-reducing agents.

133. The therapeutic administration system of claim 119, further comprising:

an implant-site-targeting dispenser responsive to the decision whether to administer the one or more clot-reducing agents.

145. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:

one or more instructions operable by the processor to signal at least an anticoagulant of the one or more clot-reducing agents in response to an apparent flow degradation; and

one or more instructions operable by the processor to cause one or more dispensations in response to an apparent problem in the flow-change-indicative measurement.

146. The therapeutic administration system of claim 145, further comprising:

an implantable valve comprising at least a first dispenser operable for dispensing at least a lytic material;

a second dispenser operable for targeting an implant site; and

a wireless-communication device operable for communicating a selection of the first dispenser or the second dispenser.

147. The therapeutic administration system of claim 119, further comprising:

an implantable valve comprising at least a first dispenser operable for dispensing at least a lytic material;

a second dispenser operable for targeting an implant site by dispensing at least the lytic material; and

a wireless-communication device operable for communicating a selection of the first dispenser or the second dispenser.

323. The therapeutic administration system of claim 119, further comprising:

a thrombolytic-agent-containing dispenser responsive to the decision whether to administer the one or more clot-reducing agents.

324. The therapeutic administration system of claim 119, further comprising:

an implant-site-targeting dispenser responsive to the decision whether to administer the one or more clot-reducing agents.

325. The therapeutic administration system of claim 122 in which the one or more instructions operable by the processor to obtain a flow-change-indicative measurement comprise:

one or more instructions operable by the processor to obtain a turbulence-indicative auditory value as the flow-change-indicative measurement.

326. The therapeutic administration system of claim 123 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:

one or more instructions operable by the processor to cause one or more dispensations in response to an apparent problem in the flow-change-indicative measurement.

327. The therapeutic administration system of claim 123, further comprising:

a thrombolytic-agent-containing dispenser responsive to the decision whether to administer the one or more clot-reducing agents.

328. The therapeutic administration system of claim 125 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:

one or more instructions operable by the processor to cause one or more dispensations in response to an apparent problem in the flow-change-indicative measurement.

329. The therapeutic administration system of claim 128, further comprising:

a thrombolytic-agent-containing dispenser responsive to the decision whether to administer the one or more clot-reducing agents.

330. The therapeutic administration system of claim 128, further comprising:

a wireless-communication device.

331. The therapeutic administration system of claim 130 in which the one or more instructions operable by the processor to obtain a flow-change-indicative measurement comprise:

one or more instructions operable by the processor to obtain a turbulence-indicative auditory value as the flow-change-indicative measurement.

332. The therapeutic administration system of claim 131 in which the one or more instructions operable by the processor to obtain a flow-change-indicative measurement comprise:

one or more instructions operable by the processor to obtain a turbulence-indicative auditory value as the flow-change-indicative measurement.

333. The therapeutic administration system of claim 131 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:

one or more instructions operable by the processor to signal at least an anticoagulant of the one or more clot-reducing agents in response to an apparent flow degradation.

334. The therapeutic administration system of claim 132 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:

one or more instructions operable by the processor to signal at least an anticoagulant of the one or more clot-reducing agents in response to an apparent flow degradation.

335. The therapeutic administration system of claim 133 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:

one or more instructions operable by the processor to cause one or more dispensations in response to an apparent problem in the flow-change-indicative measurement.

336. The therapeutic administration system of claim 133, further comprising:

a wireless-communication device.

337. The therapeutic administration system of claim 133, further comprising:

a thrombolytic-agent-containing dispenser responsive to the decision whether to administer the one or more clot-reducing agents.

134-144. -144. (canceled)

148-162. -162. (canceled)

163-173. -173. (canceled)

174-176. -176. (canceled)

177. A therapeutic administration method comprising:

obtaining a flow-change-indicative measurement; and

signaling a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement.

178. The therapeutic administration method of claim 177 in which the obtaining a flow-change-indicative measurement comprises:

programming an implantable device.

179. The therapeutic administration method of claim 177 in which the obtaining a flow-change-indicative measurement comprises:

obtaining a turbulence-indicative auditory value as the flow-change-indicative measurement.

180. The therapeutic administration method of claim 177 in which the obtaining a flow-change-indicative measurement comprises:

detecting one or more conditions optically.

181. The therapeutic administration method of claim 177 in which the obtaining a flow-change-indicative measurement comprises:

detecting one or more force-change-indicative values.

182. The therapeutic administration method of claim 177 in which the signaling a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprises:

deciding upon at least one of the one or more clot-reducing agents in response to obtaining an anomalous value as the flow-change-indicative measurement.

183. The therapeutic administration method of claim 177 in which the signaling a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprises:

signaling at least an anticoagulant of the one or more clot-reducing agents in response to an apparent flow degradation.

184. The therapeutic administration method of claim 177 in which the signaling a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprises:

causing one or more dispensations in response to an apparent problem in the flow-change-indicative measurement.

190. The therapeutic administration method of claim 177 in which the signaling a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprises:

deciding upon at least one of the one or more clot-reducing agents in response to obtaining an anomalous value as the flow-change-indicative measurement;

signaling at least an anticoagulant of the one or more clot-reducing agents in response to an apparent flow degradation; and

causing one or more dispensations in response to an apparent problem in the flow-change-indicative measurement.

185-189. -189. (canceled)

191-322. -322. (canceled)